Brahma Natarajan1, Daphna Spiegel1, Elizabeth M Nichols2, Steven Feigenberg2, Rachel Blitzblau1, Gloria Broadwater3, Eileen A Duffy1, Jay A Baker4, Janet K Horton5. 1. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. 2. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. 3. Biostatistics: Duke Cancer Institute, Durham, North Carolina. 4. Department of Radiology, Duke University Medical Center, Durham, North Carolina. 5. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Electronic address: janet.horton@duke.edu.
Abstract
PURPOSE: To evaluate the mammographic sequelae of preoperative accelerated partial breast irradiation (APBI) delivered via either stereotactic radiosurgery or a conventionally fractionated regimen. METHODS AND MATERIALS: This multicenter, retrospective study evaluated surveillance mammograms from patients enrolled in 2 prospective, preoperative APBI clinical trials. At 1 site, 31 patients with cT1N0 invasive carcinomas or low- or intermediate-grade ductal carcinoma in situ (<2 cm) received preoperative stereotactic radiosurgery and had a total of 186 mammograms available for review. At the second site, 180 mammograms from 25 patients with cT1-2 (<3 cm) unifocal invasive carcinomas treated with conventionally fractionated, preoperative APBI were reviewed. Findings were compared with those of 26 early stage breast cancers treated with conventional postoperative whole breast radiation therapy. RESULTS: At a median follow-up of 61 months, 17 patients (55%) treated with single-dose APBI exhibited exuberant fat necrosis at the lumpectomy site. Fat necrosis was believed to be clinically palpable in 5 (16%) of these patients within the first 3 years of follow-up. Exuberant fat necrosis developed in 5 patients (20%) treated with fractionated APBI over a median 68-month follow-up period but only 2 of those patients (8%) who underwent conventional whole breast radiation therapy. CONCLUSIONS: In situ tumor targeting in the preoperative setting allows relative sparing of normal tissue but results in a larger and more vigorous area of change on surveillance imaging, potentially reflecting the interaction of surgical resection with an irradiated tissue bed. High-dose stereotactic radiosurgery in particular increases the risk of developing a uniquely robust and well-demarcated pattern of fat necrosis on mammogram that may also present clinically. With many ongoing studies evaluating the preoperative treatment approach, defining the landscape of expected imaging sequelae will provide useful anticipatory guidance for clinicians and patients.
PURPOSE: To evaluate the mammographic sequelae of preoperative accelerated partial breast irradiation (APBI) delivered via either stereotactic radiosurgery or a conventionally fractionated regimen. METHODS AND MATERIALS: This multicenter, retrospective study evaluated surveillance mammograms from patients enrolled in 2 prospective, preoperative APBI clinical trials. At 1 site, 31 patients with cT1N0 invasive carcinomas or low- or intermediate-grade ductal carcinoma in situ (<2 cm) received preoperative stereotactic radiosurgery and had a total of 186 mammograms available for review. At the second site, 180 mammograms from 25 patients with cT1-2 (<3 cm) unifocal invasive carcinomas treated with conventionally fractionated, preoperative APBI were reviewed. Findings were compared with those of 26 early stage breast cancers treated with conventional postoperative whole breast radiation therapy. RESULTS: At a median follow-up of 61 months, 17 patients (55%) treated with single-dose APBI exhibited exuberant fat necrosis at the lumpectomy site. Fat necrosis was believed to be clinically palpable in 5 (16%) of these patients within the first 3 years of follow-up. Exuberant fat necrosis developed in 5 patients (20%) treated with fractionated APBI over a median 68-month follow-up period but only 2 of those patients (8%) who underwent conventional whole breast radiation therapy. CONCLUSIONS: In situ tumor targeting in the preoperative setting allows relative sparing of normal tissue but results in a larger and more vigorous area of change on surveillance imaging, potentially reflecting the interaction of surgical resection with an irradiated tissue bed. High-dose stereotactic radiosurgery in particular increases the risk of developing a uniquely robust and well-demarcated pattern of fat necrosis on mammogram that may also present clinically. With many ongoing studies evaluating the preoperative treatment approach, defining the landscape of expected imaging sequelae will provide useful anticipatory guidance for clinicians and patients.
Authors: Janet K Horton; Rachel C Blitzblau; Sua Yoo; Joseph Geradts; Zheng Chang; Jay A Baker; Gregory S Georgiade; Wei Chen; Sharareh Siamakpour-Reihani; Chunhao Wang; Gloria Broadwater; Jeff Groth; Manisha Palta; Mark Dewhirst; William T Barry; Eileen A Duffy; Jen-Tsan A Chi; E Shelley Hwang Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-14 Impact factor: 7.038
Authors: Elizabeth Nichols; Susan B Kesmodel; Emily Bellavance; Cynthia Drogula; Katherine Tkaczuk; Randi J Cohen; Wendla Citron; Michelle Morgan; Paul Staats; Steven Feigenberg; William F Regine Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: M Ruch; J Brade; C Schoeber; U Kraus-Tiefenbacher; A Schnitzer; D Engel; F Wenz; M Sütterlin; S O Schoenberg; K Wasser Journal: Breast Date: 2009-10 Impact factor: 4.380
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: Vratislav Strnad; Oliver J Ott; Guido Hildebrandt; Daniela Kauer-Dorner; Hellen Knauerhase; Tibor Major; Jaroslaw Lyczek; Jose Luis Guinot; Jürgen Dunst; Cristina Gutierrez Miguelez; Pavel Slampa; Michael Allgäuer; Kristina Lössl; Bülent Polat; György Kovács; Arnt-René Fischedick; Thomas G Wendt; Rainer Fietkau; Marion Hindemith; Alexandra Resch; Anna Kulik; Leo Arribas; Peter Niehoff; Fernando Guedea; Annika Schlamann; Richard Pötter; Christine Gall; Martina Malzer; Wolfgang Uter; Csaba Polgár Journal: Lancet Date: 2015-10-19 Impact factor: 79.321
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321